# Precigen, Inc.: financial statements, quarterly

PGEN · Nasdaq · CIK 1356090 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pgen.md) · [Financials](/companies/pgen/financials.md) · [Filings](/companies/pgen/filings.md) · [Insiders](/companies/pgen/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pgen/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [1.3](/filings/0001356090-26-000017.md) | [0.9](/filings/0001356090-26-000030.md) | not reported | not reported | [23.3](/filings/0001356090-26-000017.md) | [55.0](/filings/0001356090-26-000030.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | [10.5](/filings/0001356090-26-000017.md) | [11.5](/filings/0001356090-26-000030.md) | not reported | not reported | [5.6](/filings/0001356090-26-000017.md) | [7.3](/filings/0001356090-26-000030.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | [12.4](/filings/0001356090-26-000017.md) | [16.1](/filings/0001356090-26-000030.md) | not reported | not reported | [21.0](/filings/0001356090-26-000017.md) | [22.2](/filings/0001356090-26-000030.md) |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | [(22.6)](/filings/0001356090-26-000017.md) | [(31.8)](/filings/0001356090-26-000030.md) | not reported | not reported | [(6.0)](/filings/0001356090-26-000017.md) | [22.6](/filings/0001356090-26-000030.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001356090-26-000017.md) | [0.0](/filings/0001356090-26-000030.md) | not reported | not reported | [2.9](/filings/0001356090-26-000017.md) | [3.0](/filings/0001356090-26-000030.md) |
| Income tax | $m | [(0.0)](/filings/0001356090-24-000026.md) | [(0.3) d](/filings/0001356090-26-000009.md) | [(0.0)](/filings/0001356090-25-000019.md) | [(1.7)](/filings/0001356090-25-000024.md) | [0.0](/filings/0001356090-25-000034.md) | [(0.1) d](/filings/0001356090-26-000009.md) | [0.0](/filings/0001356090-26-000017.md) | [0.0](/filings/0001356090-26-000030.md) | [0.0](/filings/0001356090-25-000034.md) | not reported | [0.0](/filings/0001356090-26-000017.md) | [0.0](/filings/0001356090-26-000030.md) |
| Net income | $m | [(19.8)](/filings/0001356090-24-000026.md) | [(33.1) d](/filings/0001356090-26-000009.md) | [(23.7)](/filings/0001356090-25-000019.md) | [(58.8)](/filings/0001356090-25-000024.md) | [(24.0)](/filings/0001356090-25-000034.md) | [(19.7) d](/filings/0001356090-26-000009.md) | [(54.2)](/filings/0001356090-26-000017.md) | [(26.6)](/filings/0001356090-26-000030.md) | [(146)](/filings/0001356090-25-000034.md) | [(23.5) d](/filings/0001356090-26-000009.md) | [(7.9)](/filings/0001356090-26-000017.md) | [20.1](/filings/0001356090-26-000030.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001356090-24-000026.md) | not reported | [(0.10)](/filings/0001356090-25-000019.md) | [(0.23)](/filings/0001356090-25-000024.md) | [(0.09)](/filings/0001356090-25-000034.md) | not reported | [(0.18)](/filings/0001356090-26-000017.md) | [(0.09)](/filings/0001356090-26-000030.md) | [(1.06)](/filings/0001356090-25-000034.md) | not reported | [(0.02)](/filings/0001356090-26-000017.md) | [0.05](/filings/0001356090-26-000030.md) |
| Basic EPS | $ per share | [(0.08)](/filings/0001356090-24-000026.md) | not reported | [(0.10)](/filings/0001356090-25-000019.md) | [(0.23)](/filings/0001356090-25-000024.md) | [(0.09)](/filings/0001356090-25-000034.md) | not reported | [(0.18)](/filings/0001356090-26-000017.md) | [(0.09)](/filings/0001356090-26-000030.md) | [(1.06)](/filings/0001356090-25-000034.md) | not reported | [(0.02)](/filings/0001356090-26-000017.md) | [0.06](/filings/0001356090-26-000030.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [10.1](/filings/0001356090-23-000017.md) | [7.6](/filings/0001356090-25-000007.md) | [17.5](/filings/0001356090-24-000010.md) | [9.3](/filings/0001356090-24-000017.md) | [24.7](/filings/0001356090-24-000026.md) | [29.5](/filings/0001356090-26-000009.md) | [6.1](/filings/0001356090-25-000019.md) | [13.8](/filings/0001356090-25-000024.md) | [14.3](/filings/0001356090-25-000034.md) | [30.2](/filings/0001356090-26-000030.md) | [7.5](/filings/0001356090-26-000017.md) | [16.3](/filings/0001356090-26-000030.md) |
| Current assets | $m | [93.0](/filings/0001356090-23-000017.md) | [68.8](/filings/0001356090-25-000007.md) | [49.5](/filings/0001356090-24-000010.md) | [23.7](/filings/0001356090-24-000017.md) | [34.5](/filings/0001356090-24-000026.md) | [102](/filings/0001356090-26-000009.md) | [84.6](/filings/0001356090-25-000019.md) | [62.8](/filings/0001356090-25-000024.md) | [130](/filings/0001356090-25-000034.md) | [115](/filings/0001356090-26-000030.md) | [102](/filings/0001356090-26-000017.md) | [134](/filings/0001356090-26-000030.md) |
| Total assets | $m | [191](/filings/0001356090-23-000017.md) | [151](/filings/0001356090-25-000007.md) | [135](/filings/0001356090-24-000010.md) | [73.2](/filings/0001356090-24-000017.md) | [83.5](/filings/0001356090-24-000026.md) | [145](/filings/0001356090-26-000009.md) | [129](/filings/0001356090-25-000019.md) | [102](/filings/0001356090-25-000024.md) | [171](/filings/0001356090-25-000034.md) | [156](/filings/0001356090-26-000030.md) | [139](/filings/0001356090-26-000017.md) | [170](/filings/0001356090-26-000030.md) |
| Current liabilities | $m | [32.9](/filings/0001356090-23-000017.md) | [23.0](/filings/0001356090-25-000007.md) | [28.8](/filings/0001356090-24-000010.md) | [23.0](/filings/0001356090-24-000017.md) | [21.2](/filings/0001356090-24-000026.md) | [21.5](/filings/0001356090-26-000009.md) | [24.0](/filings/0001356090-25-000019.md) | [23.2](/filings/0001356090-25-000024.md) | [32.1](/filings/0001356090-25-000034.md) | [37.3](/filings/0001356090-26-000030.md) | [21.1](/filings/0001356090-26-000017.md) | [29.4](/filings/0001356090-26-000030.md) |
| Total liabilities | $m | [43.0](/filings/0001356090-23-000017.md) | [32.5](/filings/0001356090-25-000007.md) | [37.8](/filings/0001356090-24-000010.md) | [30.0](/filings/0001356090-24-000017.md) | [28.1](/filings/0001356090-24-000026.md) | [78.5](/filings/0001356090-26-000009.md) | [113](/filings/0001356090-25-000019.md) | [108](/filings/0001356090-25-000024.md) | [129](/filings/0001356090-25-000034.md) | [135](/filings/0001356090-26-000030.md) | [118](/filings/0001356090-26-000017.md) | [127](/filings/0001356090-26-000030.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001356090-26-000009.md) | not reported | not reported | [92.9](/filings/0001356090-25-000034.md) | [93.2](/filings/0001356090-26-000030.md) | [93.5](/filings/0001356090-26-000017.md) | [93.9](/filings/0001356090-26-000030.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [0.0](/filings/0001356090-23-000017.md) | [0.0](/filings/0001356090-24-000007.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [148](/filings/0001356090-24-000026.md) | [118](/filings/0001356090-26-000009.md) | [97.0](/filings/0001356090-25-000024.md) | [43.2](/filings/0001356090-25-000034.md) | [55.4](/filings/0001356090-25-000034.md) | [38.5](/filings/0001356090-26-000030.md) | [(14.1)](/filings/0001356090-26-000030.md) | [(36.8)](/filings/0001356090-26-000030.md) | [41.9](/filings/0001356090-25-000034.md) | [20.9](/filings/0001356090-26-000030.md) | [20.2](/filings/0001356090-26-000030.md) | [43.6](/filings/0001356090-26-000030.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(17.0) d](/filings/0001356090-24-000026.md) | [(15.8) d](/filings/0001356090-26-000009.md) | [(14.1)](/filings/0001356090-25-000019.md) | [(23.1) d](/filings/0001356090-25-000024.md) | [(22.7) d](/filings/0001356090-25-000034.md) | [(8.2) d](/filings/0001356090-26-000009.md) | [(16.3)](/filings/0001356090-26-000017.md) | [(19.0) d](/filings/0001356090-26-000030.md) | [(29.1) d](/filings/0001356090-25-000034.md) | [(23.5) d](/filings/0001356090-26-000009.md) | [(43.8)](/filings/0001356090-26-000017.md) | [(17.8) d](/filings/0001356090-26-000030.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001356090-24-000026.md) | [1.0 d](/filings/0001356090-26-000009.md) | [4.4](/filings/0001356090-25-000019.md) | [2.3 d](/filings/0001356090-25-000024.md) | [0.9 d](/filings/0001356090-25-000034.md) | [1.0 d](/filings/0001356090-26-000009.md) | [0.6](/filings/0001356090-26-000017.md) | [1.0 d](/filings/0001356090-26-000030.md) | [0.4 d](/filings/0001356090-25-000034.md) | [0.0 d](/filings/0001356090-26-000009.md) | [0.3](/filings/0001356090-26-000017.md) | [0.4 d](/filings/0001356090-26-000030.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [201](/filings/0001356090-23-000017.md) | [230](/filings/0001356090-24-000010.md) | [248](/filings/0001356090-24-000017.md) | [249](/filings/0001356090-24-000026.md) | [249](/filings/0001356090-25-000019.md) | [252](/filings/0001356090-25-000024.md) | [276](/filings/0001356090-25-000034.md) | [294](/filings/0001356090-26-000017.md) | [296](/filings/0001356090-26-000030.md) | [307](/filings/0001356090-25-000034.md) | [354](/filings/0001356090-26-000017.md) | [414](/filings/0001356090-26-000030.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 358,035,247 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001356090-26-000030.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.